U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07887971) titled 'A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors' on Oct. 15.
Brief Summary: This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
ES-SCLC
Small Cell Lung Cancer Extensive Stage
B7H3
Prostate Cancer
HNSCC
mCRPC (Metastatic Castration-re...